Why Is GRAIL INC EQUITY Equity (GRAL) Stock Down Today?

Why GRAL stock is down today

GRAIL Inc. shares fell 10.90% to $137.28 on Friday, marking a sharp reversal in a stock that had risen 10.5% over the previous eight sessions. The decline came amid a mix of near-term data expectations and internal sales by top executives.

What Happened

GRAIL announced it will present new NHS-Galleri and PATHFINDER 2 data on its multi-cancer early detection blood test at the Early Detection of Cancer Conference (EDCC) in October 2026 and the ESMO Congress later that month. The company highlighted these planned readouts as key to demonstrating the performance and real-world application of its Galleri test. However, the stock moved lower on the day as investors appeared to price in the time horizon for these results, which are not expected until late 2026.

Meanwhile, the CEO and CFO of GRAIL both sold shares in recent weeks, with Joshua J. Ofman (CEO) selling on August 27 and September 21, and Aaron Freidin (CFO) selling on September 21. These insider transactions totaled $7.5 million in the last 90 days, with no insider purchases recorded during the same period.

What The Data Shows

GRAIL’s stock has traded between $41.50 and $156.49 over the past 52 weeks, and the stock has printed 30 fresh 52-week lows on October 6. The stock has a market capitalization of $6.4 billion and remains unprofitable, with a trailing twelve-month earnings per share of -9.75 and a net margin of -236.9%. Revenue has grown 23.1% in the same period. The stock’s beta of 3.25 indicates high volatility relative to the market.

What To Watch

GRAIL has no upcoming earnings report to note, but coverage breadth remains active. Investors should monitor the company’s data presentations at EDCC and ESMO in October 2026 for potential catalysts.